JP2014527400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527400A5 JP2014527400A5 JP2014517664A JP2014517664A JP2014527400A5 JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5 JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014517664 A JP2014517664 A JP 2014517664A JP 2014527400 A5 JP2014527400 A5 JP 2014527400A5
- Authority
- JP
- Japan
- Prior art keywords
- diabetes
- apociii
- population
- secreting cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501480P | 2011-06-27 | 2011-06-27 | |
| US61/501,480 | 2011-06-27 | ||
| PCT/EP2012/062371 WO2013000920A2 (en) | 2011-06-27 | 2012-06-26 | Methods for treating and/or limiting development of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527400A JP2014527400A (ja) | 2014-10-16 |
| JP2014527400A5 true JP2014527400A5 (enExample) | 2015-06-11 |
| JP6242790B2 JP6242790B2 (ja) | 2017-12-06 |
Family
ID=46331358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517664A Expired - Fee Related JP6242790B2 (ja) | 2011-06-27 | 2012-06-26 | 糖尿病の治療および／または発症抑制を行うための候補化合物を同定する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US8557513B2 (enExample) |
| EP (1) | EP2724155B1 (enExample) |
| JP (1) | JP6242790B2 (enExample) |
| KR (1) | KR101937260B1 (enExample) |
| CN (1) | CN103620404B (enExample) |
| WO (1) | WO2013000920A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| WO2014095875A1 (en) * | 2012-12-18 | 2014-06-26 | Per Olof Berggren | Methods for treating and/or limiting development of diabetes |
| JP2014161257A (ja) * | 2013-02-22 | 2014-09-08 | Univ Of Tokyo | 多能性幹細胞から膵ランゲルハンス島を製造する方法 |
| US9783600B2 (en) | 2013-02-25 | 2017-10-10 | Imbp Holding, Llc | Apolipoprotein C3 (ApoCIII) antagonists and methods of their use to remove ApoCIII inhibition of lipoprotein lipase (LPL) |
| WO2014140113A1 (en) * | 2013-03-13 | 2014-09-18 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| KR20150046852A (ko) * | 2013-10-23 | 2015-05-04 | 삼성전자주식회사 | 전자 장치 및 전자 장치의 암호를 이용한 인증 방법 |
| KR102206054B1 (ko) * | 2014-05-09 | 2021-01-21 | 삼성전자주식회사 | 지문 처리 방법 및 그 전자 장치 |
| US9474951B2 (en) * | 2015-01-21 | 2016-10-25 | William Chuang | Golf tee structures, assemblies, and systems with improved accuracy |
| US9700617B2 (en) | 2015-02-09 | 2017-07-11 | Biocrine Ab | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis |
| JP7341916B2 (ja) * | 2015-04-01 | 2023-09-11 | ビーエーエスエフ エーエス | アポｃ３を低下させるためのチアオキソ化合物の使用 |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| BR112020008514A2 (pt) | 2017-10-31 | 2020-10-20 | Staten Biotechnology B.V. | anticorpos anti-apoc3 e métodos de uso dos mesmos |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| SG11202100186RA (en) * | 2018-07-19 | 2021-02-25 | Biocrine Ab | Methods and reagents for treating diabetes |
| US11310268B2 (en) | 2019-05-06 | 2022-04-19 | Secureworks Corp. | Systems and methods using computer vision and machine learning for detection of malicious actions |
| US11381589B2 (en) | 2019-10-11 | 2022-07-05 | Secureworks Corp. | Systems and methods for distributed extended common vulnerabilities and exposures data management |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| US20030083242A1 (en) * | 1998-11-06 | 2003-05-01 | Alphonse Galdes | Methods and compositions for treating or preventing peripheral neuropathies |
| CZ304320B6 (cs) * | 1999-12-22 | 2014-03-05 | The Scripps Research Institute | Farmaceutický prostředek obsahující bílkoviny tyrozin kinázy Src a Yes, společně s farmaceuticky přijatelným nosičem a předmět výroby |
| JP4351043B2 (ja) * | 2001-07-09 | 2009-10-28 | エラン ファーマシューティカルズ，インコーポレイテッド | アミロイド毒性の阻害方法 |
| US9062306B2 (en) | 2003-04-29 | 2015-06-23 | Biocrine Ab | Methods for identifying compounds for treating type 1 diabetes |
| US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
| CN101166981A (zh) * | 2005-04-11 | 2008-04-23 | 阿斯利康(瑞典)有限公司 | 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒 |
| US20090060843A1 (en) | 2007-08-31 | 2009-03-05 | Biocrine Ab | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes |
| US20110008901A1 (en) * | 2009-07-07 | 2011-01-13 | Kiernan Urban A | Apolipoprotein ciii in pre- and type 2 diabetes |
| US8557513B2 (en) * | 2011-06-27 | 2013-10-15 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
-
2012
- 2012-06-25 US US13/532,601 patent/US8557513B2/en not_active Expired - Fee Related
- 2012-06-26 EP EP12729166.4A patent/EP2724155B1/en active Active
- 2012-06-26 KR KR1020147000028A patent/KR101937260B1/ko not_active Expired - Fee Related
- 2012-06-26 WO PCT/EP2012/062371 patent/WO2013000920A2/en not_active Ceased
- 2012-06-26 CN CN201280028829.1A patent/CN103620404B/zh not_active Expired - Fee Related
- 2012-06-26 JP JP2014517664A patent/JP6242790B2/ja not_active Expired - Fee Related
-
2013
- 2013-09-13 US US14/026,145 patent/US9068973B2/en active Active
-
2015
- 2015-05-20 US US14/717,903 patent/US9353183B2/en active Active
-
2016
- 2016-01-14 US US14/995,645 patent/US20160194634A1/en not_active Abandoned
- 2016-01-14 US US14/995,341 patent/US9744232B2/en active Active
-
2017
- 2017-07-26 US US15/660,340 patent/US10226530B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527400A5 (enExample) | ||
| Gibb et al. | Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation | |
| Takahashi et al. | Cancer cells co-opt the neuronal redox-sensing channel TRPA1 to promote oxidative-stress tolerance | |
| Faget et al. | Unmasking senescence: context-dependent effects of SASP in cancer | |
| Wasserman et al. | The vasculature in prediabetes | |
| Bhattacharyya et al. | FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling | |
| Salpeter et al. | Systemic regulation of the age-related decline of pancreatic β-cell replication | |
| Xiao et al. | EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis | |
| Varga et al. | Antitransforming growth factor-β therapy in fibrosis: recent progress and implications for systemic sclerosis | |
| Gil et al. | Heparanase is essential for the development of diabetic nephropathy in mice | |
| Chau et al. | MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways | |
| Alimonti et al. | A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis | |
| Ren et al. | Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice | |
| Sotgia et al. | Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms | |
| Omote et al. | Role of the TNF pathway in the progression of diabetic nephropathy in KK-Ay mice | |
| Helman et al. | Effects of ageing and senescence on pancreatic β‐cell function | |
| Zhou et al. | Wnt/β-catenin signaling and renin–angiotensin system in chronic kidney disease | |
| Gugliucci et al. | The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease | |
| Andres et al. | Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs | |
| Porteiro et al. | Hepatic p63 regulates steatosis via IKKβ/ER stress | |
| WO2013000920A3 (en) | Methods for identifying candidate compounds for treating and/or limiting development of diabetes | |
| O’Reilly et al. | Senescence and tissue fibrosis: Opportunities for therapeutic targeting | |
| Rosselot et al. | Myc is required for adaptive β-cell replication in young mice but is not sufficient in one-year-old mice fed with a high-fat diet | |
| Cannatà et al. | Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation | |
| Koga et al. | The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice |